NDAORALTABLET
Approved
Feb 2015
Lifecycle
Peak
Competitive Pressure
8/100
Mechanism of Action
fixed-dose combination of the HIV‑1 antiretroviral agents abacavir, dolutegravir, and lamivudine [see Microbiology ()].
Indications (2)
Loss of Exclusivity
LOE Date
Sep 11, 2029
42 months away
Patent Expiry
Sep 11, 2029
Patent Records (2)
| Patent # | Expiry | Type | Use Code |
|---|---|---|---|
| 7754731 | Mar 11, 2029 | SubstanceProduct | U-1663 |
| 7754731*PED | Sep 11, 2029 | — |